Audited Supplier
Synthesis Material Intermediates
Pharmaceutical Intermediates
Cool Dry Place
Yellow Powder
Industrial
GMP, Hse, ISO 9001, USP, Bp
Within 24 Hours After Receiving The Payment
>99%
Jinan Andechem
25kg/Drum
25kg/500kg/1000kg
China
29147000
Product Description
| Product Name | Atovaquone |
| CAS No. | 95233-18-4 |
| MF | C22H19ClO3 |
| Appearance | Yellow Powder |
| Packing | 1KG/Bag |
| Specification | BP, USP, EP |
| Shelf life | 2 Years |
Atovaquone is an orally active antiprotozoal agent indicated for patients with mild to moderate AIDS-associated Pneumocystis carinii pneumonia who are intolerant to the fist-line therapy of trimethoprim-sulfamethoxazole. It is also under investigation as a treatment for malaria and AIDS-associated toxoplasmosis.The hydroxynaphthoquinone atovaquone, which exhibits antimalarial and anti-Pneumocystis activity, is an electron transport inhibitor that causes depletion of the ATP pool. The primary effect is on the iron flavoprotein dihydro-orotate dehydrogenase, an essential enzyme in the production of pyrimidines. Mammalian cells are able to avoid undue toxicity by use of preformed pyrimidines. Dihydro-orotate dehydrogenase from Plasmodium falciparum is inhibited by concentrations of atovaquone that are very much lower than those needed to inhibit the Pneumocystis enzyme, raising the possibility that the antimicrobial consequences might differ in the two organisms. Although atovaquone was originally developed as a monotherapy for malaria, high level resistance readily emerges in Plasmodium falciparum when the drug is used alone. Consequently, atovaquone is now combined with proguanil.
